CORRECTING and REPLACING — Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD


LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit "µg" were mistakenly represented as "mg." The corrected release follows:

Go here to see the original:
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Related Posts